Lb Pharmaceuticals (LBRX) Depreciation & Amortization (CF) (2025 - 2026)
Lb Pharmaceuticals (LBRX) recorded quarterly Depreciation & Amortization (CF) of $82000.0 in Q1 2026, up 3.8% quarter-over-quarter from $79000.0 in Q1 2025, and up 3.8% on a YoY basis from $79000.0 in Q1 2025.
Lb Pharmaceuticals (LBRX) Depreciation & Amortization (CF) (2025 - 2026) Analysis & Trends
Lb Pharmaceuticals' Depreciation & Amortization (CF) history runs 2 years deep, the most recent figure standing at $82000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 3.8% year-over-year to $82000.0; the TTM figure through Mar 2026 stood at $161000.0 (changed N/A YoY), while the FY2025 annual figure was $321000.0, up 252.75% from the prior year.
- Depreciation & Amortization (CF) was $82000.0 for Q1 2026 at Lb Pharmaceuticals, up from $79000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $82000.0 in Q1 2026 to a low of $79000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Lb Pharmaceuticals | 843.30 Mn | 843.30 Mn | - | 82,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82,000.00 |
| Mar 31, 2026 | 82,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Mar 31, 2025 | 79,000.00 |